Meloxicam in Combination with Mitoxantrone or Vinblastine as First-Line Treatment for Non-Resectable Urothelial Cell Carcinoma in Dogs.
COX inhibitor
bladder cancer
canine
chemotherapy
oncology
Journal
Veterinary sciences
ISSN: 2306-7381
Titre abrégé: Vet Sci
Pays: Switzerland
ID NLM: 101680127
Informations de publication
Date de publication:
21 Aug 2023
21 Aug 2023
Historique:
received:
08
06
2023
revised:
14
08
2023
accepted:
16
08
2023
medline:
25
8
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
epublish
Résumé
Cyclooxygenase (COX) inhibitors have been demonstrated to have antitumour activity in canine urothelial cell carcinoma (UCC), given as a sole treatment or in combination with chemotherapy. The purpose of this retrospective multi-institutional study was to assess the efficacy of meloxicam in combination with mitoxantrone or vinblastine as a first-line treatment for non-resectable canine UCC. Gastrointestinal adverse effects (AEs) of these treatment combinations were also assessed. A total of 28 dogs met the inclusion criteria, 21/28 dogs received mitoxantrone and meloxicam, and 7/28 received vinblastine and meloxicam. Tumour response (TR) and AE were evaluated according to Veterinary Co-Operative Oncology Group (VCOG) criteria. The endpoint of the study was the time to tumour progression (TTP). The mitoxantrone-group induced 24% partial response and 62% stable disease, while the vinblastine-group induced 14% and 86%, respectively. Median TTP was 84 days (mitoxantrone and meloxicam, 70 days; and vinblastine and meloxicam, 178 days). The presence of metastatic disease significantly decreased TTP (
Identifiants
pubmed: 37624316
pii: vetsci10080529
doi: 10.3390/vetsci10080529
pmc: PMC10458788
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer Chemother Pharmacol. 2000;46(3):221-6
pubmed: 11021739
J Vet Intern Med. 2013 Jan-Feb;27(1):126-33
pubmed: 23205923
Urol Oncol. 2000 Mar-Apr;5(2):47-59
pubmed: 21227289
Pathol Oncol Res. 2007;13(4):365-9
pubmed: 18158574
J Am Vet Med Assoc. 2013 Jun 1;242(11):1534-8
pubmed: 23683018
Vet J. 2015 Aug;205(2):217-25
pubmed: 25747698
ILAR J. 2014;55(1):100-18
pubmed: 24936033
Vet Comp Oncol. 2005 Jun;3(2):73-80
pubmed: 19379215
Vet Rec. 2008 Feb 2;162(5):159-61
pubmed: 18245750
Vet Comp Oncol. 2015 Sep;13(3):176-83
pubmed: 23534501
J Am Vet Med Assoc. 2012 Dec 15;241(12):1627-32
pubmed: 23216038
J Comp Pathol. 2019 Jul;170:1-9
pubmed: 31375151
J Vet Intern Med. 1994 Jul-Aug;8(4):273-8
pubmed: 7983623
J Vet Intern Med. 2015 Jan;29(1):261-7
pubmed: 25619518
Best Pract Res Clin Gastroenterol. 2001 Oct;15(5):801-20
pubmed: 11566042
Vet Comp Oncol. 2021 Jun;19(2):311-352
pubmed: 33427378
J Small Anim Pract. 2013 Feb;54(2):67-74
pubmed: 23286739
Vet Anaesth Analg. 2012 Jan;39(1):69-90
pubmed: 22151877
J Am Vet Med Assoc. 2007 Oct 1;231(7):1056-60
pubmed: 17916030
J Vet Intern Med. 2011 Nov-Dec;25(6):1385-90
pubmed: 22092632
Vet J. 2015 Jul;205(1):69-73
pubmed: 26004824
Bladder Cancer. 2016 Apr 27;2(2):241-250
pubmed: 27376143
J Am Vet Med Assoc. 2011 Apr 15;238(8):1004-10
pubmed: 21492043
Vet Comp Oncol. 2022 Jun;20(2):449-457
pubmed: 34878687
Am J Vet Res. 2000 May;61(5):478-81
pubmed: 10803639
Med Res Rev. 2011 Mar;31(2):161-201
pubmed: 19967720
Cancer Lett. 2014 May 01;346(2):217-24
pubmed: 24486220
J Am Vet Med Assoc. 2011 Oct 15;239(8):1084-9
pubmed: 21985349
Expert Opin Ther Pat. 2015;25(12):1357-71
pubmed: 26566186
Clin Cancer Res. 2003 Feb;9(2):906-11
pubmed: 12576466
J Small Anim Pract. 2006 Jan;47(1):14-20
pubmed: 16417605
Mol Cancer Ther. 2003 Feb;2(2):183-8
pubmed: 12589035
Cancer Chemother Pharmacol. 1992;29(3):214-8
pubmed: 1733554